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Osteopontin mediates obesity-induced
adipose tissue macrophage infiltration and
insulin resistance in mice
Takashi Nomiyama,1 Diego Perez-Tilve,2 Daisuke Ogawa,1 Florence Gizard,1 Yue Zhao,1
Elizabeth B. Heywood,1 Karrie L. Jones,1 Ryuzo Kawamori,3 Lisa A. Cassis,4
Matthias H. Tschöp,2 and Dennis Bruemmer1,4
1Division

of Endocrinology and Molecular Medicine, University of Kentucky College of Medicine, Lexington, Kentucky, USA. 2Obesity Research Center,
Department of Psychiatry, Genome Research Institute, University of Cincinnati, Cincinnati, Ohio, USA. 3Department of Medicine,
Metabolism and Endocrinology, Juntendo University School of Medicine, Tokyo, Japan. 4Graduate Center for Nutritional Sciences,
University of Kentucky, Lexington, Kentucky, USA.

Obesity is associated with a state of chronic, low-grade inflammation characterized by abnormal cytokine
production and macrophage infiltration into adipose tissue, which may contribute to the development of
insulin resistance. During immune responses, tissue infiltration by macrophages is dependent on the expression of osteopontin, an extracellular matrix protein and proinflammatory cytokine that promotes monocyte
chemotaxis and cell motility. In the present study, we used a murine model of diet-induced obesity to examine
the role of osteopontin in the accumulation of adipose tissue macrophages and the development of insulin
resistance during obesity. Mice exposed to a high-fat diet exhibited increased plasma osteopontin levels, with
elevated expression in macrophages recruited into adipose tissue. Obese mice lacking osteopontin displayed
improved insulin sensitivity in the absence of an effect on diet-induced obesity, body composition, or energy
expenditure. These mice further demonstrated decreased macrophage infiltration into adipose tissue, which
may reflect both impaired macrophage motility and attenuated monocyte recruitment by stromal vascular
cells. Finally, obese osteopontin-deficient mice exhibited decreased markers of inflammation, both in adipose
tissue and systemically. Taken together, these results suggest that osteopontin may play a key role in linking
obesity to the development of insulin resistance by promoting inflammation and the accumulation of macrophages in adipose tissue.
Introduction
Obesity and the associated metabolic pathologies are the most
common risk factors for type 2 diabetes and subsequent cardiovascular disease (1). Unequivocal evidence has demonstrated
that obesity is associated with a state of chronic, low-grade
inflammation characterized by abnormal cytokine production
and activation of inflammatory signaling pathways in adipose
tissue (2). Recent studies indicated that adipose tissue macrophages (ATMs) accumulating during diet-induced obesity (DIO)
are not only an important source of adipose tissue inflammation
but also alter insulin sensitivity in adipocytes: Weisberg et al.
identified macrophage accumulation in obese adipose tissue
and suggested that these macrophages are derived from the
circulation (3). A critical observation made by Xu et al. further
characterized these macrophages as an important mediator of
insulin resistance (4). Collectively, these studies support the
concept that ATMs infiltrating into obese adipose tissue from
the circulation are a key source of inflammation in obesity and
provide a causal link between obesity and the development of
adipose tissue insulin resistance (5).
Nonstandard abbreviations used: AF, adipocyte fraction; ATM, adipose tissue macrophage; CCR2, C-C motif chemokine receptor 2; DIO, diet-induced obesity; EWAT,
epididymal white adipose tissue; HFD, high-fat diet; LFD, low-fat diet; MCP-1, monocyte chemoattractant protein 1; OPN, osteopontin; PAI-1, plasminogen activator
inhibitor 1; RQ, respiratory quotient; SVF, stromal vascular fraction.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. 117:2877–2888 (2007). doi:10.1172/JCI31986.
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The observation that macrophages infiltrate adipose tissue
from the circulation has focused attention on the mechanisms
by which these cells are recruited into obese adipose tissue (3).
Accumulating evidence over the last decade has demonstrated
that macrophage recruitment during inflammatory processes is
dependent on the expression of osteopontin (OPN) (6–9). OPN
is a secreted matrix glycoprotein and proinflammatory cytokine
that has previously been characterized as a major component of
cell-mediated immunity (8). Its ability to interact with integrin
surface receptors through an Arg-Gly-Asp (RGD) sequence and
with the CD44 receptor has established OPN as an important
attachment and signaling molecule (10, 11). In bone tissue, for
example, OPN facilitates the attachment of osteoclasts to the
matrix (12). In addition to its role in bone metabolism, a variety
of studies have provided evidence that OPN is highly secreted
by macrophages at sites of inflammation where it mediates
monocyte adhesion (12), migration (7), differentiation (13),
and phagocytosis (14). Using OPN-deficient mice crossed to
atherosclerosis-prone apoE–/– mice, we (9) and others (15) have
further recently demonstrated that OPN deficiency attenuates the development of atherosclerosis. In these studies OPN
expression was found to be essential for monocyte motility and
inflammatory gene expression; in particular, OPN deficiency
in macrophages decreased the development of atherosclerosis
(9). It is now well recognized that OPN induces chemotaxis of
monocytes and promotes cellular motility via direct interaction
with its receptors (10, 11).
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Figure 1
OPN plasma levels in DIO and expression of OPN in adipose tissue. C57BL/6 mice (n = 10/group) were fed a LFD or HFD for 20 weeks. (A) OPN
plasma levels were analyzed by ELISA and data expressed as mean ± SEM. #P < 0.005. (B) Adipose tissues were isolated and OPN mRNA
expression was analyzed in whole EWAT, the AF, and the SVF. Data are presented as relative OPN mRNA expression normalized to TFIIB
mRNA expression and are expressed as mean ± SEM. *P < 0.05, compared with LFD. (C) SVFs isolated from EWATs of obese wild-type mice
(n = 6) were pooled and separated into macrophages, endothelial cells, and preadipocytes using magnetic immunoaffinity isolation. Cell fractions
were analyzed for OPN (black bars, left y axis) and CD68 (white bars, right y axis) mRNA expression. Data are presented as mRNA expression
relative to TFIIB mRNA expression and are expressed as mean ± SEM. **P < 0.01 compared with preadipocyte or endothelial cell fraction. (D)
Paraffin-embedded EWAT was analyzed for OPN immunoreactivity and F4/80-positive macrophage content. Sections were counterstained with
hematoxylin and images obtained at the indicated magnifications.

Based on the evidence that obesity is associated with infiltration
(3) and activation (16) of macrophages in adipose tissue combined
with recent studies characterizing OPN as an important component of cell-mediated immune responses and monocyte motility
(10, 11), we investigated the expression of OPN in adipose tissue
and examined the role of OPN for macrophage accumulation
in adipose tissue. Since macrophages and associated proinflammatory cytokines contribute to adipose tissue insulin resistance
during DIO (4), we further analyzed the effect of OPN deficiency
on systemic insulin resistance. Using a murine model of DIO, we
report that OPN secretion is increased during obesity and highly
expressed in ATMs, characterizing OPN as a cytokine secreted
by adipose tissue. OPN deficiency attenuated ATM content, adipose tissue, and systemic inflammation and improved insulin
resistance. These studies outline a previously unrecognized role
for OPN in mediating ATM recruitment and identify OPN as an
important link between adipose tissue–derived inflammatory processes and insulin resistance.
2878
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Results
OPN expression in adipose tissue increases during DIO. To analyze
whether OPN plasma levels change during DIO, C57BL/6 wildtype mice (n = 10/group) were maintained either on a low-fat diet
(LFD; 10% kcal from fat) or high-fat diet (HFD; 60% kcal from
fat) for 20 weeks. Compared with the LFD group, mice fed a HFD
gained 26.1 g after a 20-week feeding period (28.2 ± 4.1 versus
54.3 ± 5.3 g; P < 0.005). As depicted in Figure 1A, OPN plasma levels analyzed by ELISA were significantly elevated in obese mice fed
a HFD compared with the lean control mice fed a LFD (15.2 ± 0.8
versus 4.3 ± 0.3 pg/ml, respectively; P < 0.005).
Epididymal white adipose tissue (EWAT) from these mice was
next analyzed for OPN mRNA expression to examine whether the
OPN transcript is expressed in adipose tissue and whether this is
modulated by the obese phenotype. In mice fed a LFD, OPN mRNA
expression levels were negligible in whole adipose tissues as well in
fractionated tissues (Figure 1B). However, feeding a HFD resulted in
a significant 8.1-fold (P < 0.01) increase of OPN transcript levels in
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Figure 2
DIO and body composition in wild-type OPN+/+ and OPN–/– mice. (A)
Wild-type OPN+/+ (black symbols, n = 12) and OPN–/– (white symbols,
n = 12) mice were fed a LFD (circles) or HFD (squares). Weight gain
was followed for 25 weeks and data expressed as mean ± SEM. Body
composition (fat mass, lean mass, and body mass) before (B) and
after (C) feeding a HFD (n = 7–8/group) was analyzed in OPN+/+ (black
bars) and OPN–/– (white bars) mice by quantitative NMR. Data are presented as mean ± SEM. #P < 0.05, compared with OPN+/+ mice.

whole adipose tissues. Separation of the adipose tissue demonstrated that there was a profound 35.9-fold (P < 0.001) increase of OPN
mRNA in the stromal vascular fraction (SVF). In contrast, there was
an insignificant 2.2-fold increase (P = 0.091) of OPN in the adipocyte
fraction (AF), indicating that the increase of OPN mRNA in whole
adipose tissue was primarily due to an increase of transcript levels
in the SVF. The observation that OPN mRNA expression in the AF
increased only modestly during DIO prompted us to corroborate
these findings in vitro and to analyze the regulation of OPN during the differentiation of 3T3-L1 preadipocytes. Use of this model
system revealed that OPN mRNA levels decrease during the differentiation process (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI31986DS1).
Previous studies have indicated that PPARγ activation suppresses
OPN transcription in macrophages (17). Since PPARγ expression is
induced during adipocyte differentiation, we analyzed the transcripThe Journal of Clinical Investigation

tional regulation of a 2-kb OPN promoter construct by PPARγ in
3T3-L1 preadipocytes. Interestingly, both ligand-induced activation
of PPARγ and overexpression of a constitutively active PPARγ suppressed OPN promoter activity (Supplemental Figure 2), providing
a potential mechanism for the observed decrease of OPN transcript
levels during adipocyte differentiation.
Given the high expression of OPN mRNA in the SVF, we next
characterized the cell types expressing OPN within the SVF using
magnetic immunoaffinity isolation of ATMs, endothelial cells, and
preadipocytes. Analysis of expression of CD68 mRNA encoding a
110-kDa transmembrane glycoprotein that is highly expressed by
monocytes and tissue macrophages (18) confirmed that 95.1% of
the CD68 mRNA in the SVF was found in the macrophage fraction
(Figure 1C). Using this approach, OPN mRNA expression in the
SVF was primarily observed in macrophage isolates, while considerably less OPN mRNA was detected in the preadipocyte fraction
and in the endothelial cell fraction.
To confirm that OPN is expressed by ATMs, we performed
immunohistochemistry on epididymal fat pads isolated from obese
C57BL/6 mice fed a HFD for 3 months. As the majority of studies
analyzing ATM content in murine models previously employed an
antibody raised against the F4/80 antigen (3, 19), a marker specific
for mature macrophages (20), we stained consecutive sections for
F4/80 and OPN. Negative controls included lack of chromogen
development following incubation with the same concentrations of
control nonimmune IgG in the presence of the secondary antibody
or incubation with the primary antibody in absence of the secondary
antibody (data not shown). As reported recently (3), DIO was associated with the accumulation of macrophages that were frequently
observed in obese adipose tissue forming crown-like aggregates surrounding adipocytes (Figure 1D). Staining for OPN revealed a striking similarity with F4/80 immunoreactivity, and higher magnification of serial sections confirmed OPN expression in F4/80 positive
macrophages. In concert, these results suggest that OPN plasma
levels increase during obesity and that during DIO OPN mRNA is
primarily expressed by ATMs accumulating in adipose tissue.
OPN deficiency does not affect DIO. To further determine the role of
OPN for the development of DIO, adipose tissue inflammation,
and insulin resistance, we next fed male OPN–/– and littermate
wild-type OPN+/+ mice (n = 12/group) either a LFD or a HFD for
25 weeks. Consistent with our previous studies (9), there were no
differences in weights between OPN–/– and OPN+/+ mice at baseline or after feeding a LFD for 25 weeks. In mice fed a HFD for 25
weeks, there was a statistically nonsignificant trend toward lower
body mass in the OPN–/– mice compared with OPN+/+ wild-type
mice (54.6 ± 4.1 versus 56.2 ± 4.8 g, respectively; P = 0.087; Figure
2A). To examine whether there are differences in lean or fat mass,
we analyzed body composition in OPN–/– and OPN+/+ mice using
NMR before (Figure 2B) and after (Figure 2C) feeding a HFD. This
approach revealed no difference in fat mass between lean or obese
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Table 1
Food intake, energy expenditure, RQ, and locomotor activity of animals in this study
Parameter

Cycle

Before HFD

After HFD

OPN+/+

OPN–/–

OPN+/+

OPN–/–

Food intake (g)

Total
Light
Dark

10.2 ± 0.7
3.9 ± 0.6
6.2 ± 0.2

9.7 ± 1.1
4.2 ± 0.7
5.5 ± 0.8

5.7 ± 0.8
1.5 ± 0.3
4.2 ± 0.8

6.8 ± 0.7
2.9 ± 0.5A
3.8 ± 0.3

Energy expenditure (kcal/kg)

Total
Light
Dark

711.5 ± 17.5
334.1 ± 12.2
393.4 ± 7.4

733.8 ± 22.5
346.9 ± 11.2
402.6 ± 12.5

770.3 ± 16.8
367.3 ± 8.1
419.3 ± 10.7

847.4 ± 26.4
419.2 ± 11.4
444.6 ± 16.2

RQ (vCO2/vO2)

Total
Light
Dark

0.862 ± 0.010
0.827 ± 0.016
0.900 ± 0.015

0.876 ± 0.016
0.836 ± 0.016
0.909 ± 0.016

0.773 ± 0.011
0.745 ± 0.016
0.856 ± 0.010

0.796 ± 0.011
0.815 ± 0.013A
0.847 ± 0.011

Locomotor activity
(light beam breaks)

Total
Light
Dark

34,857.1 ± 1,996.1
11,994.7 ± 422.1
22,862.4 ± 1,892.1

28,367.1 ± 2,268.5
11,713.5 ± 1,317.2
16,653.6 ± 1,561.7

32,993.4 ± 3,230.1
10,164.1 ± 632.2
21,149.0 ± 2,446.6

24,489.4 ± 2,748.5
6,409.6 ± 568.1
17,461.8 ± 1,983.1

OPN+/+ wild-type and OPN–/– mice (n = 7–8/group) were analyzed before (at 8 weeks of age, while on standard chow diet) and after feeding a HFD. Data is
expressed as mean ± SEM. AP < 0.05, OPN–/– compared with OPN+/+.

OPN–/– and OPN+/+ mice. However, compared with wild-type mice,
there was a modest but significant decrease in lean body mass of
OPN–/– mice in the absence of a difference in whole body mass.
Therefore, OPN deficiency had no effect on the development of
DIO in mice fed a HFD.
We next analyzed whether OPN deficiency affects energy metabolism by recording cumulative measurements for food intake,
energy expenditure, respiratory quotient (RQ), and locomotor
activity (Table 1). Initial recordings were obtained at 8 weeks of
age on mice fed a standard chow diet, followed by measurements
after feeding OPN–/– and wild-type OPN+/+ a HFD for 20 weeks.
Consistent with the observed lack of any overt differences in whole
body mass and adiposity, no statistically significant differences in
total food intake, energy expenditure, RQ, or locomotor activity
were observed. However, OPN–/– mice showed a modestly increased
RQ during the 12-hour light cycle, indicating slightly higher carbohydrate utilization on HFD. This effect was likely a consequence
of increased light phase food intake in the OPN–/– mice fed a HFD,
as both increased RQ and food intake disappeared when analyzed
over the entire 24-hour period.
OPN deficiency improves insulin sensitivity. HFD feeding and DIO in
mice is associated with the development of insulin resistance (21),
and to further explore whether insulin resistance is affected by
OPN deficiency, we analyzed metabolic parameters in OPN–/– and
wild-type OPN+/+ mice. No significant differences were observed in

fasting blood glucose or plasma insulin concentrations between
OPN–/– and OPN+/+ mice fed a LFD for 25 weeks (Table 2). Both
plasma glucose and insulin levels significantly increased in obese
wild-type mice fed a HFD. In contrast, in OPN–/– mice fed a HFD,
plasma glucose levels were normal and insulin levels were significantly lower compared with the obese OPN+/+ wild-type mice
fed a HFD. Furthermore, HFD feeding in wild-type OPN+/+ mice
resulted in a significant increase in triglyceride levels, which was
normalized in OPN–/– mice.
To further confirm that obese OPN–/– mice are more insulin sensitive, we next analyzed glucose clearance following an
intraperitoneal injection of insulin as a measure of insulin sensitivity. In these experiments, the insulin response in mice fed a LFD
was not significantly affected by the genotype, although OPN–/–
mice tended to be slightly more insulin sensitive. In obese OPN+/+
mice fed a HFD, glucose levels decreased by 16.4% 60 minutes after
insulin injection, whereas levels decreased by 49.3% in OPN–/– mice,
indicating that the absence of OPN improved insulin sensitivity
in obese mice (Figure 3A). The maximal insulin response after 60
minutes in obese OPN–/– mice fed a HFD reached levels observed in
mice fed a LFD. Similarly, intraperitoneally injected glucose during an intraperitoneal glucose tolerance test was cleared faster and
more effectively in obese OPN–/– mice compared with OPN+/+ (Figure 3B). In concert, these data confirm that insulin sensitivity is
increased in obese OPN–/– compared with wild-type OPN+/+ mice.

Table 2
Metabolic parameters of mice examined in this study
Parameter

Cholesterol (mg/dl)
Triglycerides (mg/dl)
Glucose (mg/dl)
Insulin (pg/ml)

OPN+/+

LFD
OPN–/–

P
OPN+/+ vs.
OPN–/–

OPN+/+

HFD
OPN–/–

P
OPN+/+ vs.
OPN–/–

P
OPN+/+ LFD
vs. HFD

P
OPN–/– LFD
vs. HFD

183.3 ± 11.7
55.1 ± 5.4
94.4 ± 4.7
159.1 ± 39.1

183.4 ± 7.2
77.9 ± 14.5
101.8 ± 9.3
183.2 ± 37.1

0.342
0.751
0.292
0.541

145.3 ± 16.2
112.9 ± 7.9
113.0 ± 4.3
1,976.4 ± 425.5

166.1 ± 11.1
57.8 ± 5.6
99.7 ± 5.6
609.6 ± 105.9

0.751
0.009
0.044
0.041

0.342
0.026
0.033
0.023

0.227
0.227
0.683
0.046

Wild-type OPN+/+ and OPN–/– mice were fed a LFD or HFD for 25 weeks. Blood samples were obtained after an overnight fasting period and analyzed. Data
is presented as mean ± SEM.
2880
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Figure 3
Insulin sensitivity in OPN+/+ and OPN–/– mice. OPN+/+ (black symbols)
and OPN–/– (white symbols) mice were fed a LFD (dashed lines) or
HFD (solid lines) for 25 weeks. (A) Insulin sensitivity in these mice
(n = 6/group) was determined at the end of the feeding period following
an intraperitoneal injection of insulin (1 U/kg body weight). (B) Glucose
clearance (n = 6/group) was analyzed following an intraperitoneal challenge of 1 g/kg body weight glucose. Data are presented as mean
blood glucose concentration ± SEM. #P < 0.05, OPN–/– compared with
OPN+/+ mice fed HFD.

OPN deficiency decreases macrophage accumulation in obese adipose tissue.
It has previously been demonstrated that ATMs accumulate during
DIO, resulting in obesity-associated insulin resistance (3, 4). The
evidence that OPN mediates the recruitment of macrophages in tissues (6–9) prompted us to further investigate the cause of increased
insulin sensitivity in obese OPN–/– mice and to determine whether
OPN-deficient mice were protected from adipose tissue inflammation during obesity. We first analyzed macrophage content in epididymal adipose tissue pads isolated from OPN–/– and OPN+/+ mice
fed a LFD and HFD by immunohistochemical analysis. In epididymal adipose tissues no overt differences in adipocyte size or numbers between genders were noted. Using an absorbed rabbit antimouse macrophage antiserum, we observed a profound increase in
ATM number in obese OPN+/+ wild-type mice fed a HFD (Figure 4A).
Typically, immunohistochemistry localized macrophages in crownlike clusters surrounding adipocytes. Despite having a similar fat
mass following HFD feeding, obese epididymal adipose tissues isolated from OPN-deficient mice accumulated strikingly fewer ATMs
(Figure 4A, lower panel). As the majority of studies analyzing ATM
content in murine models have used an antibody against the F4/80
antigen (3, 19), we further sought to corroborate these observations
using staining for F4/80. As depicted in Figure 4B, the majority
of cells surrounding adipocytes expressed F4/80, and this immunoreactivity correlated with the staining obtained using the rabbit
anti-mouse macrophage antiserum. When F4/80-positive ATMs
were further quantified as a percentage of total cell number (Figure
4C), epididymal adipose tissue from obese OPN–/– mice fed a HFD
contained fewer macrophages compared with wild-type OPN+/+ mice
(19.1% ± 2.0% versus 36.8% ± 3.1%; P < 0.005).
The Journal of Clinical Investigation

To further confirm this observation we next analyzed the macrophage content in whole and fractionated epididymal adipose
tissue by quantitative real-time RT-PCR for CD68. As expected,
CD68 mRNA increased during DIO in whole adipose isolated
from OPN+/+ mice (Figure 4D). High CD68 mRNA expression
was detected in the SVF while transcript levels were negligible in
the AF of both genotypes. Consistent with the data obtained by
immunohistochemistry, CD68 mRNA transcript levels were significantly decreased in both whole adipose tissue and the SVF
isolated from obese OPN–/– mice compared with wild-type OPN+/+
mice. In concert, immunohistochemistry and quantitative RT-PCR
indicate that OPN deficiency prevents ATM accumulation during
DIO, although macrophage content is not completely rescued to
the level of lean mice fed a LFD.
OPN mediates chemotaxis and amplifies monocyte chemoattractant
protein 1–induced macrophage migration. OPN promotes cell motility and chemoattraction (6, 7, 9, 22), and so we next analyzed the
effect of OPN deficiency on macrophage chemotaxis. Wild-type
macrophage migration increased by 1.67 ± 0.21-fold (P < 0.05)
when OPN was provided as substrate (Figure 5A). When cells were
exposed to monocyte chemoattractant protein 1 (MCP-1), transwell
migration of wild-type macrophages increased by 1.77 ± 0.12-fold
(P < 0.05). MCP-1–induced chemotaxis was further increased by
2.41 ± 0.28-fold in the presence of OPN (P < 0.01). In comparison,
OPN-deficient macrophages were hypomotile, and basal migration was only 62.6% ± 2.26% that of the wild-type cells (P < 0.05).
Although OPN–/– macrophages migrated by 1.94 ± 0.12-fold
(P < 0.05) when recombinant OPN was provided, exogenous OPN
only partially restored the wild-type phenotype. Furthermore,
OPN-deficient macrophages failed to respond to MCP-1, which
was only modestly restored in the presence of extracellular OPN
(2.54 ± 0.32-fold increase versus baseline; P < 0.01). We further
sought to confirm these observations ex vivo and analyzed migration of macrophages wild-type for OPN toward stromal vascular
cells isolated from OPN+/+ and OPN–/– mice fed a LFD or HFD for 25
weeks. As depicted in Figure 5B, macrophage migration to stromal
vascular cells isolated from obese wild-type mice was significantly
increased 3.1 ± 0.6-fold relative to migration toward cells isolated
from lean mice (P < 0.05). Compared with the migratory response
elicited by stromal vascular cells of obese wild-type mice, transwell
macrophage migration was significantly decreased to 53.3% ± 3.2%
when macrophages migrated toward stromal vascular cells isolated from obese OPN–/– mice (P < 0.05). In concert, these experiments indicate that OPN amplifies MCP-1–directed macrophage
chemotaxis and that OPN deficiency in stromal vascular cells alters
obesity-induced macrophage recruitment.
OPN–/– mice are protected from obesity-associated adipose tissue and systemic inflammation. Since accumulating evidence outlines a key role
of DIO in the development of low-grade systemic inflammation
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Figure 4
OPN deficiency decreases ATM content in obese mice. (A) ATM content was determined by immunohistochemical analysis of epididymal
adipose tissues isolated from OPN+/+ and OPN–/– mice fed a LFD or HFD. Adipose tissues were stained using an absorbed rabbit anti-mouse
macrophage antiserum (original magnification, ×100). (B) Epididymal adipose tissues from obese OPN+/+ and OPN–/– mice were analyzed for
macrophage content using an F4/80 antibody (magnified as indicated). (C) Macrophage content was quantified by analyzing the fraction of
F4/80-stained cells relative to total number of cells in epididymal adipose tissue from OPN+/+ (black bars) and OPN–/– (white bars) mice fed a
LFD or HFD (n = 8/group). Values are expressed as mean ± SEM. (D) Macrophage content was quantitatively assessed by real-time RT-PCR
for CD68 mRNA expression in EWAT, the AF, and the SVF isolated from OPN+/+ (black bars) and OPN–/– (white bars) mice (n = 12/group) fed
a LFD or HFD for 25 weeks. Data are presented as relative CD68 mRNA expression normalized to TFIIB mRNA expression and are expressed
as mean ± SEM. *P < 0.05, HFD compared with LFD; #P < 0.05, OPN–/– mice compared with OPN+/+ mice fed HFD.

(2), we further sought to investigate whether OPN deficiency and
associated attenuation of macrophage accumulation in adipose
tissue affects obesity-induced adipose tissue inflammation. As
depicted in Figure 6, no significant differences in the expression
of the inflammatory genes IL-6, TNF-α, MCP-1, and iNOS were
observed between lean OPN+/+ and OPN–/– mice fed a LFD. However, HFD feeding and the development of DIO in OPN+/+ mice
markedly increased the expression of these inflammatory genes.
Consistent with less ATM accumulation, IL-6, TNF-α, and iNOS
gene expression levels in adipose tissues isolated from obese OPN–/–
mice were significantly decreased. Similarly, MCP-1 expression
levels revealed a trend to decrease in obese OPN–/– mice, although
this was not statistically significant. These data suggest that
2882
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the obesity-associated increase of the inflammatory genes IL-6,
TNF-α, and iNOS in adipose tissue is OPN dependent.
We next determined the role of OPN for obesity-associated systemic inflammation and analyzed TNF-α, IL-6, MCP-1, and plasminogen activator inhibitor 1 (PAI-1) plasma levels in OPN–/– and
wild-type OPN+/+ mice fed a LFD or HFD. TNF-α plasma levels
were below detection limit in almost all samples analyzed using
the mouse adipokine LincoPlex assay system (Figure 7A). Similarly, in lean mice fed a LFD, plasma levels of IL-6 and MCP-1 were
below detection limit but increased to a detectable level in obese
mice. PAI-1 plasma levels significantly increased in OPN+/+ mice
upon feeding a HFD. In OPN–/– mice fed a HFD, however, plasma
levels of IL-6, MCP-1, and PAI-1 were significantly lower compared
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Figure 5
Chemotaxis of macrophages isolated from OPN+/+ and OPN–/– mice. (A)
Peritoneal macrophages from OPN+/+ and OPN–/– mice were subjected
to chemotaxis assays in modified Boyden chambers. Membranes of
the transwell chambers were coated either with the substrate poly-Dlysine (PDL) as control or with recombinant OPN (5 ng/ml). Following
attachment of the macrophages to the membrane, vehicle or MCP-1
(50 ng/ml) was added to the media in the lower chamber. Transwell
migration was analyzed after 2 hours and expressed as cell numbers
per HPF (×200). Experiments were repeated 4 times in triplicate. Data
are expressed as mean ± SEM. *P < 0.05 compared with PDL alone;
#P < 0.05 compared with OPN alone; §P < 0.05 compared with OPN+/+.
(B) Stromal vascular cells were isolated from epididymal adipose tissues
harvested from OPN+/+ (black bars) and OPN–/– (white bars) mice fed a
LFD or HFD for 25 weeks (n = 6/group). Cells were cultured in the bottom chambers, and peritoneal macrophages from wild-type mice were
added to the insert. Migration was analyzed in triplicate after 2 hours as
described in A. Data are expressed as mean ± SEM. †P < 0.05, compared with LFD; ‡P < 0.05, compared with OPN+/+ mice fed HFD.

sensitivity in obese OPN–/– mice is likely the result of decreased
ATM content, resulting in attenuated local and systemic inflammation rather than changes in insulin-sensitizing adipokine levels.

with those of wild-type OPN+/+ mice. These data reveal that OPN
modulates obesity-induced systemic inflammation by decreasing
IL-6, MCP-1, and PAI-1 plasma levels.
Finally, we determined systemic levels of 3 adipokines that have
been implicated in insulin sensitivity (23, 24). Adiponectin plasma
levels decreased with the development of DIO and insulin resistance. Although there was a trend toward elevated adiponectin
levels in LFD- and HFD-fed OPN–/– mice compared with wild-type
mice, this trend was not statistically significant. Compared with
lean mice fed a LFD, serum leptin and resistin concentrations
increased in obese HFD-fed mice and did not significantly differ
between both genotypes (Figure 7B). Therefore, increased insulin

Discussion
OPN is a chemokine-like, extracellular matrix–associated protein
involved in monocyte motility and the inflammatory immune
response (10, 11). Since its initial cloning in 1986 (25), OPN has
been associated with a remarkable range of pathologic responses
(10); however, its role in obesity and metabolic disorders has not,
to our knowledge, previously been investigated. In the present
study, we demonstrate expression of OPN in adipose tissue and
outline what we believe to be a previously unrecognized role for
OPN to mediate obesity-associated ATM recruitment, adipose tissue inflammation, and resulting insulin resistance.
A host of adipose tissue–generated adipokines and cytokines
have been identified that have emerged as an important source of
systemic inflammation in obesity (2). We report here that OPN
expression in adipose tissue increases with obesity and that plasma
levels increase during the development of DIO OPN, suggesting a
potential novel function of OPN for obesity-associated inflammatory and metabolic changes in adipose tissue. OPN plasma levels
are elevated in various inflammatory diseases, including atherosclerosis (26), inflammatory bowel disease (27), granulomatous
inflammatory diseases (28), rheumatoid arthritis (29), and mul-

Figure 6
Inflammatory gene expression in adipose tissues from OPN+/+ and
OPN–/– mice. OPN+/+ and OPN–/– mice were fed a LFD or HFD for 25
weeks. mRNA expression levels of the indicated inflammatory genes
were analyzed in EWATs isolated from OPN+/+ (black bars) and OPN–/–
(white bars) mice fed a LFD or OPN+/+ (dark gray) and OPN–/– mice
(light gray) fed a HFD (n = 6/group). Data are presented as relative
mRNA normalized to TFIIB mRNA and expressed as mean ± SEM.
*P < 0.05, HFD compared with LFD; #P < 0.05, OPN–/– mice compared
with OPN+/+ mice fed HFD.
The Journal of Clinical Investigation
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Figure 7
Plasma cytokine and adipokine levels in OPN+/+ and OPN–/–
mice. (A) IL-6, MCP-1, and PAI-1 plasma levels were analyzed
in OPN+/+ (black bars) and OPN–/– (white bars) mice (n = 10/
group) fed either a LFD or a HFD. (B) Plasma adiponectin,
leptin, and resistin levels were analyzed in plasma obtained
from mice described in A. Data are presented as mean ± SEM.
*P < 0.05, compared with LFD; #P < 0.05 compared with OPN+/+
mice fed HFD.

tiple sclerosis (30). OPN is rapidly expressed after cellular activation, and it is abundantly secreted by activated macrophages but
not resting macrophages or monocytes (31, 32). Consistent with
this notion, we observed that OPN expression in obese adipose tissue colocalized with macrophages and that OPN mRNA was highly
expressed in macrophages isolated from the SVF. In contrast, we
observed only negligible OPN mRNA in adipocytes and a decline
in OPN transcript levels with differentiation of 3T3-L1 adipocytes.
Although OPN is expressed in proliferating fibroblasts (33), these
observations confirm earlier reports documenting decreased OPN
mRNA levels in differentiated adipocytes as compared with preadipocytes (34). Interestingly, OPN has previously been characterized as a PPARγ target gene in macrophages, and overexpression
of PPARγ or ligand treatment with a thiazolidinedione suppresses
OPN transcription (17). PPARγ expression increases with differentiation of adipocytes, and when we overexpressed PPARγ in 3T3-L1
fibroblasts, thiazolidinedione treatment decreased OPN promoter
activity. Similarly, overexpression of a constitutively active PPARγ
mutant suppressed basal OPN promoter activity. Thus PPARγmediated downregulation of OPN could provide a mechanism for
the observed decline in OPN mRNA expression during the differentiation process of preadipocytes into mature adipocytes.
Using a model of DIO, our studies revealed that OPN has no
effect on the development of obesity and does not affect food
intake or energy metabolism. Consistent with several recent studies (9, 35, 36), total body weights were similar in wild-type and
OPN-deficient mice. However, in previous studies body composition was not analyzed, and an unexpected but interesting and consistent observation in both lean and obese animals was a slightly
2884
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decreased lean body mass in OPN–/– mice. Our experiments
employed NMR technology to provide measures of body fat
mass, fat-free mass, and water content (37). Considering the
limitation of this technique to distinguish different fat-free
tissue masses including bone and muscle, the reason for the
slightly decreased lean body mass in OPN–/– mice remains
elusive. OPN deficiency renders mice less sensitive to bone
resorption (36, 38). Thus this knowledge and the observation that bone density analyzed by micro-CT is not affected
by OPN deficiency in unstressed mice (38) argues against
a contribution of OPN deficiency in bone tissue to the
observed decrease in lean body mass. To date no studies have
determined whether OPN affects total body muscle mass.
Therefore, it will be important for the determination of the
mechanisms by which OPN deletion modulates lean body
mass to characterize fat-free tissue masses in OPN-deficient
mice and perform further studies using newly available techniques including NMR to analyze total body composition.
In bone marrow transplantation studies, Weisberg et al.
have recently provided evidence that the majority of ATMs
are derived from the circulation (3). The MCP-1/C-C motif
chemokine receptor 2 (MCP-1/CCR2) axis is well established to
regulate macrophage recruitment to sites of inflammation (39,
40), and MCP-1 is secreted from adipocytes and plasma levels are
increased in obesity (41). In addition, MCP-1 levels secreted from
adipocytes correlate with adipocyte size (42), indicating that the
MCP-1/CCR2 cascade is likely among the earliest mechanisms
involved in the recruitment of monocytes to adipose tissue. This is
further supported by recent studies demonstrating that adipocytespecific MCP-1 overexpression results in enhanced macrophage
infiltration of adipose tissue (43, 44), while MCP-1 or CCR2 deficiency decreases macrophage content in obese adipose tissue (19,
43). However, in both models obesity-induced macrophage accumulation in adipose tissue is not normalized and macrophages
remain accumulating in the adipose tissue, suggesting that additional mechanisms are involved in this process. In this study, we
demonstrate decreased macrophage content in obese adipose tissue
from OPN–/– mice in the absence of any differences in total fat mass,
thus providing an additional mechanism by which macrophages
infiltrate adipose tissue. This requirement of OPN for macrophage
recruitment to adipose tissue is consistent with our data examining the role of OPN for macrophage chemotaxis. In wild-type macrophages OPN amplifies macrophage migration and exerts additive effects on chemotaxis in the presence of MCP-1. In contrast,
OPN-deficient macrophages are hypomotile and less responsive to
MCP-1, a phenotype that exogenous OPN is unable to completely
correct. These observations suggest that OPN augments the MCP-1
response and functions primarily in an autocrine mechanism to
promote macrophage chemotaxis. This concept is in agreement
with recent studies demonstrating that endogenous OPN expres-
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sion in macrophages is important to maintain macrophage function, including chemotaxis, differentiation, and inflammation
(13). Moreover, intracellular OPN forms a complex with the CD44
receptor and ezrin/radixin/moesin proteins at the cell membrane
of cell processes (45) that is required for cell fusion and chemotaxis
of macrophages (22). Finally, it is well recognized that OPN–/– mice
have defective granulomatous responses (8, 46) that likely involve
abnormal macrophage function.
The observation that OPN is primarily expressed by macrophages
in obese adipose tissue combined with the important autocrine
role of OPN in macrophage function suggest a model in which
endogenous OPN amplifies macrophage recruitment through
the MCP-1/CCR2 cascade in the early stages of obesity. Our ex
vivo experiments demonstrate increased macrophage chemotaxis
toward the SVF isolated from obese mice, indicating that the
continued recruitment of macrophages within the SVF may further exacerbate macrophage infiltration. In contrast, migration
toward the SVF isolated from obese OPN–/– mice was substantially
decreased. Our findings that macrophage content in the SVF
from OPN–/– mice is considerably less compared with that from
OPN+/+ mice may indicate that fewer macrophages accumulating
during the course of obesity ultimately secrete fewer migratory
signals, which would likely contribute to decreased macrophage
recruitment during later stages of obesity. In concert, these studies support an important role for OPN to promote macrophage
infiltration into obese adipose tissue. However, confirming the
contribution macrophage-dervied OPN to adipose tissue inflammation in vivo requires studies that will depend on the specific
deletion of OPN in macrophages using either bone marrow transplantation approaches or conditional OPN deletion strategies.
Concomitant with the attenuated macrophage content in obese
adipose tissue from OPN–/– mice, we documented decreased inflammatory gene expression in adipose tissue and decreased systemic
levels of the proinflammatory cytokines IL-6, MCP-1, and PAI-1.
MCP-1– and CCR2-deficient mice develop less obesity-induced
insulin resistance (19, 43), and the current understanding of the
role of ATMs and adipose tissue inflammation in obesity-induced
insulin resistance would suggest that prevention of macrophage
accumulation in adipose tissue preserves insulin sensitivity. In further support of this concept, we demonstrate that decreased ATM
accumulation in OPN-deficient mice is associated with increased
insulin sensitivity: OPN–/– mice developed less obesity-associated hyperinsulinemia, cleared glucose more rapidly following an
intraperitoneal glucose challenge, and exhibited an enhanced insulin response after an intraperitoneal injection of insulin. Importantly, these effects of OPN deficiency were observed despite the
same level of obesity in OPN–/– and wild-type mice. Increased insulin sensitivity associated with OPN deficiency was unlikely a result
of altered adipokine secretion, since plasma levels of 3 adipokines
implicated in insulin resistance (adiponectin, resistin, and leptin)
were not significantly different in OPN–/– mice. Based on the strong
recent evidence that ATMs are both necessary and sufficient for
the development of obesity-associated insulin resistance (4, 19,
43), the observed decrease in ATM content in obese OPN–/– mice
provides a likely mechanism for the increased insulin sensitivity in
these mice. Macrophages present in adipose tissue directly interfere
with insulin signaling and insulin-stimulated glucose uptake in
adipocytes by decreasing GLUT4 and insulin receptor substrate 1
(IRS-1) expression, leading to a decrease in Akt phosphorylation
and impaired insulin-stimulated GLUT4 translocation to the plasThe Journal of Clinical Investigation

ma membrane (47). Interestingly, blocking TNF-α, which is well
established to contribute to insulin resistance (48), prevents macrophage-induced alterations in adipocyte insulin signaling (47).
These observations confirm important cross-talk between ATMs
and adipocytes in mediating insulin resistance and indicate that
ATMs affect insulin signaling by perpetuating inflammatory pathways in adipocytes. While the concept of decreased ATM content
in OPN–/– mice as a mechanism for improved insulin sensitivity is
intriguing and supported by these studies, we cannot exclude that
OPN may also affect hepatic insulin sensitivity. OPN deficiency
has previously been associated with decreased hepatic fibrosis in
experimental nonalcoholic steatohepatitis (49), and since hepatic
OPN expression increases during nonalcoholic steatohepatitis
in obese mice (50), OPN deficiency may also modulate obesityinduced hepatic insulin resistance.
In summary, in the present study we characterize OPN, a versatile
mediator of macrophage motility involved in cell-mediated inflammation (9–11, 22, 51), as a novel cytokine expressed by ATMs and
secreted during DIO. OPN expression is required for macrophage
recruitment into adipose tissue and for obesity-associated adipose
tissue and systemic inflammation. Finally, we demonstrate that
decreased adipose tissue inflammation in OPN–/– mice is associated with improved obesity-associated insulin resistance without
significantly altering body mass. These data therefore identify
OPN as a previously unappreciated link between obesity, adipose
tissue inflammation, and insulin resistance.
Methods
Animals and animal care. OPN–/– mice on a BlackSwiss background, kindly
provided by C.M. Giachelli (University of Washington, Seattle, Washington, USA) and L. Liaw (Maine Medical Center Research Institute, Scarborough, Maine, USA), were used as previously described (9). C57BL/6 mice
were obtained from The Jackson Laboratory at 6–8 weeks of age. All mice
were housed in Plexiglas ventilated cages (4 animals/cage) within a pathogen-free barrier facility that maintained a 12-hour light/12-hour dark
cycle. Mice had access to autoclaved water and pellet food ad libitum. Prior
to 8 weeks of age, all mice were fed a standard rodent chow diet containing
approximately 5% kcal fat (Diet 7012; Harlan Teklad). At 8 weeks of age,
male OPN–/– and littermate wild-type OPN+/+ mice were fed diets containing
either 10% kcal (LFD) or 60% kcal (HFD) from fat (D12450B and D12492;
Research Diets Inc.) for 25 weeks. Weight gain during DIO was monitored
by weighing mice weekly. All animal studies were in compliance with the
Division of Laboratory Animal Research Guide for Care and Use of Laboratory Animals and were performed with the approval of the University of
Kentucky Institutional Animal Care and Use Committee.
Analysis of body composition, energy expenditure, food intake, and locomotor activity.
Mice were analyzed for body composition by quantitative NMR (37) at the
University of Cincinnati Mouse Metabolic Phenotyping Center before and
after being fed a HFD. Food intake, energy expenditure, RQ, and locomotor
activity were analyzed using a calorimetry system (LabMaster; TSE Systems).
Mice were placed in the calorimetry system and adapted for 48 hours, and
cumulative recordings were collected over the following 48 hours.
Isolation of adipose tissues. Mice fed a LFD or HFD were sacrificed by CO2
asphyxiation, and EWAT pads were removed. For adipose tissue fractionation into the SVF or AF, epididymal adipose tissue pads were minced,
placed in HEPES-buffered DMEM (Invitrogen) supplemented with 10 mg/
ml fatty acid–poor BSA (FAP-BSA; Sigma-Aldrich), and centrifuged at 500 g
for 10 minutes. Following centrifugation, samples were incubated with
840 U/g collagenase type I (Worthington Chemicals) at 37°C with gentle
agitation for 1 hour. The suspension was then passed through a sterile

http://www.jci.org

Volume 117

Number 10

October 2007

2885

Downloaded October 30, 2014 from The Journal of Clinical Investigation. doi:10.1172/JCI31986.

research article
250-μm nylon mesh (Sefar America Inc.) and centrifuged at 500 g for 10
minutes. Pelleted cells were collected as the SVF, and the floating cells were
collected as the AF. The AF was subsequently further digested for 1 hour,
washed twice with DMEM, and subjected to a second centrifugation step
as described above until there were no further cell or debris pellets. The
SVF was resuspended in erythrocyte lysis buffer, incubated at room temperature for 3 minutes, and centrifuged at 500 g for 5 minutes. For isolation of mRNA, the erythrocyte-depleted SVF and the AF were resuspended
in TRIzol reagent (Invitrogen). Separation of ATMs and endothelial cells
from SVF isolates was performed by magnetic immunoaffinity isolation
using anti-CD11b and anti-CD31 antibodies conjugated to magnetic
beads (MACS Cell Separation System; Miltenyi Biotec), respectively. Following isolation of ATMs and endothelial cells from the SVF using positive
selection columns (MS columns; Miltenyi Biotec), the remaining cells were
eluted as the preadipocyte fraction. For the analysis of OPN mRNA expression levels, eluted cell isolates were resuspended in TRIzol reagent.
Metabolic measurements. Blood samples were obtained from wild-type
OPN+/+ and OPN–/– mice after feeding a LFD or HFD for 25 weeks. The
blood was collected after an overnight fast from the retroorbital plexus or
from the abdominal vena cava at sacrifice. Plasma glucose, cholesterol, and
triglyceride concentrations were determined using commercially available
enzymatic assay kits (Wako Chemicals). Plasma levels for insulin, leptin,
resistin, IL-6, MCP-1, TNF-α, and PAI-1 were analyzed at Linco Diagnostics using the mouse adipokine assay kit. Adiponectin plasma levels were
analyzed using a mouse adiponectin ELISA kit (Linco Diagnostics). OPN
plasma levels were analyzed using a commercially available mouse OPN
EIA Kit (Assay Designs). Insulin sensitivity and glucose tolerance were
analyzed in LFD- and HFD-fed animals after an overnight fasting period
(14 hours). Following an intraperitoneal bolus injection of recombinant
human regular insulin (1 U/kg body weight) (Novolin R; Novo Nordisk Inc.), blood glucose concentrations were measured using a Freestyle
Flash Glucometer (Abbott Laboratories) before and 30, 60, 90, and 120
minutes after injection. Glucose tolerance tests were performed following
an intraperitoneal injection of dextrose dissolved in water (1 g/kg body
weight). Blood glucose levels were analyzed before and 30, 60, 90, 120, 150,
and 180 minutes following injection.
Immunohistochemistry. For histological analysis of OPN expression in adipose tissue, EWAT tissues were isolated from C57BL/6 mice fed a HFD
for 3 months. Immunohistochemistry on paraffin-embedded tissues was
performed as described in ref. 9 using antibodies for OPN (dilution of
2.5 μg/ml, catalog no. AF808; R&D Systems) and F4/80 (dilution of 1:50,
catalog no. ab6640; Abcam).
Analysis of macrophage content in epididymal adipose tissues was performed on tissue pads isolated from OPN–/– and OPN+/+ mice fed either a
LFD or HFD for 25 weeks. At sacrifice, EWAT pads were embedded in OCT
compound (Tissue-Tek; Miles Inc.) and snap-frozen. Transverse cryosections (10 μm thick) were collected at 100 μM intervals and fixed in cold
acetone. Macrophages were detected using a rabbit anti-mouse macrophage anti-serum at a dilution of 1:10,000 (catalog no. AIAD31240; Accurate Chemical & Scientific Corp.) (9) or an F4/80 antibody at a dilution of
1:50 (catalog no. ab-6640; Abcam). Two observers blinded to the experimental design performed quantification of ATM content in 5 sections
obtained from each adipose tissue pad. The total number of nuclei and the
number of nuclei of F4/80-expressing cells were counted in 10 high-power
fields (original magnification, ×200) of each section using the image analysis software ImagePro Plus (version 4.1; Media Cybernetics Inc.). The ratio
of nuclei in F4/80-positive cells and total number of nuclei in each sample
provided the fraction of ATMs for each section analyzed.
Cell culture and transient transfection. We maintained 3T3-L1 fibroblasts
(ATCC) in DMEM supplemented with 10% fetal bovine serum. Adipogene2886

The Journal of Clinical Investigation

sis was induced using standard protocols for treatment of cells with insulin
(0.1 μM), dexamethasone (1 μM), and isobutylmethylxanthine (0.5 mM).
mRNA was isolated at various time points for the analysis of OPN and
PPARγ mRNA during the differentiation process. The OPN promoter construct, wild-type PPARγ expression vector, and constitutively active PPARγ
expression vector have previously been described (52–54). We seeded 3T3L1 fibroblasts on 6-well plates and transiently cotransfected them with
1 μg DNA of the OPN promoter construct and 500 ng empty control vector,
wild-type PPARγ2 expression vector, or constitutively active PPARγ expression vector using Lipofectamine 2000 (Invitrogen). Transfection efficiency
was normalized to renilla luciferase activities generated by cotransfection
with 10 ng/well pRL-CMV (Promega). At 8 hours after transfection, cells
were treated with vehicle (DMSO) or 10 μM pioglitazone (kindly provided
by Takeda Pharmaceuticals North America). Luciferase activity was assayed
24 hours after stimulation as described in ref. 54. All experiments were
repeated at least 3 times and performed in triplicate.
Chemotaxis assays. Chemotaxis assays were performed using murine
peritoneal macrophages in a modified Boyden chamber transwell migration assay (24-well plates, 8 μm pore size; catalog no. 3422; Costar Inc.) as
described previously (9). Peritoneal macrophages from 8-week-old BlackSwiss wild-type mice were collected 3 days after injection of 1 ml of 1%
thioglycollate into the peritoneal cavity. Microporous membranes of the
transwell inserts were coated with poly-D lysine (Sigma-Aldrich) or OPN
5 ng/ml (R&D Systems) and air dried for 2 hours. Macrophages (2 × 104)
were plated to each insert in 100 μl DMEM containing 0.4% FBS, and 600
μl medium was added to each lower well. The cells were allowed to attach
to the membranes for 2 hours at 37°C in a humidified CO2 incubator, and
then the chemoattractant MCP-1 (50 ng/ml; R&D Systems) or vehicle was
added to the lower wells. In ex vivo experiments, stromal vascular cells from
EWAT pads were isolated from OPN+/+ and OPN–/– mice fed a HFD or LFD
for 25 weeks. Cells were cultured in the bottom chambers of the culture
plate, and after 2 days wild-type peritoneal macrophages were added to
the insert. In both experiments cells were allowed to migrate for 2 hours
and fixed with 2% paraformaldehyde. The non-migrating cell fraction on
the top surface of the membrane was removed with cotton swabs, while
the migrated cells were stained with hematoxylin and quantitated in triplicate sets of wells. Five randomly chosen high-power fields were counted
per membrane. Experiments were performed at least 3 times with different
preparations of macrophages and stromal vascular cells.
Reverse transcription and quantitative real-time RT-PCR. OPN, CD68, IL-6,
TNF-α, MCP-1, and iNOS mRNA expression was measured by quantitative real-time RT-PCR as indicated in Figure 1, B and C, Figure 4D,
and Figure 6. Total mRNA of these tissues was isolated using TRIzol
(Invitrogen) and reverse transcribed into cDNA as previously described
(9). PCR reactions were performed using an iCycler (Bio-Rad) and
SYBR Green I system (Bio-Rad). Each sample was analyzed in triplicate
and normalized to values for TFIIB mRNA expression. Mouse primer
sequences used were as follows: OPN, 5′-TCCCTCGATGTCATCCCTGT-3′ (forward), 5′-CCCTTTCCGTTGTTGTCCTG-3′ (reverse); CD68,
5′-CAAGGTCCAGGGAGGTTGTG-3′ (forward), 5′-CCAAAGGTAAGCTGTCCATAAGGA-3′ (reverse); IL-6, 5′-CTGCAAGAGACTTCCATCCAGTT-3′ (forward), 5′-GAAGTAGGGAAGGCCGTGG-3′ (reverse);
TNF-α, 5′-AGCCGATGGGTTGTACCT-3′ (forward), 5′-TGAGTTGGTCCCCCTTCT-3′ (reverse); MCP-1, 5′-CAGCCAGATGCAGTTAACGC3′ (forward), 5′-GCCTACTCATTGGGATCATCTTG-3′ (reverse); iNOS,
5′-GCGCTGGGCTGTACAAA-3′ (forward), 5′-AGCGTTTCGGGATCTGAAT-3′ (reverse); PPARγ, 5′-TGCTGTTATGGGTGAAACTCTG-3′ (forward), 5′- CTGTGTCAACCATGGTAATTTCTT-3′ (reverse); and TFIIB,
5′-CTCTCCCAAGAGTCACATGTCC-3′ (forward), 5′-CAATAACTCGGTCCCCTACAAC-3′ (reverse).
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Statistics. Statistical analysis for pairwise comparisons between different
genotypes or diets was performed using the 2-tailed Student’s t test. To
analyze the interaction between the genotype and the diet, 2-way ANOVA
was performed. Analyses were performed using Statistica 7 (Statsoft Inc.).
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